12 February 2024
12 February 2024
Pharma CEOs defended their high prescription drug costs, stating that the current prices are necessary for continued innovation.
Under the terms of the deal, Novo Holdings will sell three of Catalent’s fill-finish sites to Novo Nordisk, in which Novo Holdings has a controlling interest.
The Phase I trial for evaluating Hemogenyx’s CAR-T therapy to treat acute myeloid leukaemia has been cleared to begin in the US.
The approval allows for the vaccine's thawing and re-labelling by an authorised manufacturer outside of the UK's National Health Service.
Philips' has recalled a number of high profile medical devices in recent years, shaking investor confidence.
The survey by CRO Worldwide Clinical Trials shows that pharma and biotechs favour midsize contract research organisations (CROs) due to the personalised service.
The regulator granted the designation based on findings from the Phase II UNITY clinical trial.
Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
